What is Canid?
Canid is at the forefront of revolutionizing pediatric vaccine management. The company's innovative platform integrates seamlessly with electronic health record systems, employing AI and advanced software to transform the vaccine administration process into a simple scan-and-go workflow. By leveraging economies of scale, Canid aims to drastically reduce the time and financial burden associated with this critical healthcare task for pediatricians. The company's focus on streamlining a burdensome process positions it for substantial impact within the healthcare technology landscape.
How much funding has Canid raised?
Canid has raised a total of $12.5M across 3 funding rounds:
Angel/Pre-Seed
$1M
Seed
$1.5M
Series A
$10M
Angel/Pre-Seed (2021): $1M, investors not publicly disclosed
Seed (2023): $1.5M led by FJ Labs and Alumni Ventures
Series A (2025): $10M supported by Brooklyn Bridge Ventures, FJ Labs, SeedtoB Capital, and Telescope Partners
Key Investors in Canid
FJ Labs
FJ Labs specializes in angel investing at a venture scale, focusing on marketplaces and network effect businesses. They have invested in notable companies such as Alibaba, Coupang, and Rappi, building the world's largest portfolio of marketplace startups, with over 30 achieving unicorn status. The company seeks visionary founders who demonstrate passion, grit, and the ability to execute their vision. FJ Labs is committed to supporting thousands of entrepreneurs who are driving positive transformations in their industries.
Alumni Ventures
Headquartered in Manchester, New Hampshire, Alumni Ventures Group (AVG) creates and manages alumni venture capital funds at top colleges and universities. The company offers a tested playbook, structures, processes, staff, and regulatory knowledge to take the headache out of running a venture capital firm.
Brooklyn Bridge Ventures
Brooklyn Bridge Ventures is the first seed stage investment fund based in Brooklyn, NY, dedicated to fostering a community for founders and innovative professionals. As of May 2023, the fund is no longer making new investments but has previously supported a diverse portfolio of companies across various sectors. Their investments include innovative startups in areas such as grocery delivery, personal finance, and healthcare. The firm aims to connect and empower entrepreneurs while contributing to the growth of the local business ecosystem.
What's next for Canid?
With its recent major strategic investment, Canid is poised for significant expansion and further development of its AI-driven vaccine management solutions. The substantial capital infusion, totaling $12.5M, will likely fuel advancements in its technology, enhance its integration capabilities with healthcare providers, and support broader market adoption. This strategic backing suggests a trajectory towards scaling operations and solidifying its position as a leader in optimizing crucial, yet often cumbersome, healthcare workflows. The company's ability to secure such significant backing indicates strong market confidence in its innovative approach to pediatric healthcare.
See full Canid company page
